These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27142351)

  • 21. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
    Gergis U; Frenet EM; Shore T; Mayer S; Phillips A; Hsu JM; Roboz G; Ritchie E; Scandura J; Lee S; Desai P; Samuel M; Ball J; Blanco A; Romeo C; Albano MS; Dobrila L; Scaradavou A; van Besien K
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):466-473. PubMed ID: 30414955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor lymphocyte infusion in Acute Myeloid Leukemia.
    Shah NA
    Best Pract Res Clin Haematol; 2023 Sep; 36(3):101484. PubMed ID: 37612002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.
    Shrestha B; Walton K; Reff J; Sagatys EM; Tu N; Boucher J; Li G; Ghafoor T; Felices M; Miller JS; Pidala J; Blazar BR; Anasetti C; Betts BC; Davila ML
    J Clin Invest; 2020 Sep; 130(9):4652-4662. PubMed ID: 32437331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
    Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor T cell therapy in AML: How close are we?
    Gill S
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):329-333. PubMed ID: 27890255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!
    Haddad F; Daver N
    Adv Exp Med Biol; 2021; 1342():273-295. PubMed ID: 34972969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies.
    Dotti G
    Curr Opin Hematol; 2015 Nov; 22(6):489-96. PubMed ID: 26335421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
    Sinkovics JG
    Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.
    Han T; Sun Y; Liu Y; Yan C; Wang Y; Xu L; Liu K; Huang X; Zhang X
    Front Med; 2021 Oct; 15(5):728-739. PubMed ID: 34279770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of Donor Lymphocyte Infusion for Treating Relapsed High-Risk Leukemia patients after Allogeneic Hematopoietic Stem Cell Transplantation].
    Wang YX; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):982-8. PubMed ID: 26314430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
    Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
    Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.
    Gesundheit B; Shapira MY; Resnick IB; Amar A; Kristt D; Dray L; Budowski E; Or R
    Am J Hematol; 2009 Mar; 84(3):188-90. PubMed ID: 19105234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.